Personalis (NASDAQ:PSNL) CFO Aaron Tachibana Sells 51,251 Shares of Stock

by · The Cerbat Gem

Personalis, Inc. (NASDAQ:PSNL – Get Free Report) CFO Aaron Tachibana sold 51,251 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18. Following the completion of the sale, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at approximately $2,620,618.94. This trade represents a 20.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Tachibana also recently made the following trade(s):

  • On Thursday, June 4th, Aaron Tachibana sold 40,000 shares of Personalis stock. The shares were sold at an average price of $12.01, for a total transaction of $480,400.00.
  • On Friday, May 29th, Aaron Tachibana sold 38,799 shares of Personalis stock. The shares were sold at an average price of $11.58, for a total transaction of $449,292.42.

Personalis Trading Up 3.4%

Personalis stock traded up $0.43 during mid-day trading on Friday, hitting $13.02. The stock had a trading volume of 8,354,545 shares, compared to its average volume of 3,223,766. Personalis, Inc. has a one year low of $3.84 and a one year high of $13.37. The firm has a market capitalization of $1.36 billion, a P/E ratio of -12.76 and a beta of 2.28. The firm’s 50 day moving average is $8.42 and its 200 day moving average is $8.29.

Personalis (NASDAQ:PSNL – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The business had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.48 million. As a group, equities research analysts forecast that Personalis, Inc. will post -1.06 earnings per share for the current year.

Institutional Trading of Personalis

Hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd boosted its position in shares of Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after acquiring an additional 1,479 shares during the last quarter. International Assets Investment Management LLC bought a new stake in Personalis in the fourth quarter worth $31,000. Legal & General Group Plc bought a new stake in Personalis in the second quarter worth $30,000. BNP Paribas Financial Markets raised its stake in Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new stake in Personalis during the fourth quarter valued at $82,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PSNL. BTIG Research decreased their target price on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Morgan Stanley dropped their price target on Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Finally, Needham & Company LLC boosted their target price on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Read Our Latest Analysis on Personalis

About Personalis

(Get Free Report)

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

See Also